Compare Stocks: AKLI, CNXU, APYX, and RNXT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKLI Akili	$0.43	$0.43	$0.19 ▼ $1.25	$34.01M	1.72	2.20 million shs	N/A
APYX Apyx Medical	$2.90 +0.3%	$3.61	$1.70 ▼ $5.08	$122.16M	1.31	129,347 shs	161,328 shs
CNXU Conexeu Sciences	$4.46 +4.9%	$8.09	$4.19 ▼ $18.79	$119.34M	N/A	272,290 shs	114,128 shs
RNXT RenovoRx	$1.76 -0.6%	$1.29	$0.70 ▼ $2.59	$79.43M	1.12	1.46 million shs	1.16 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKLI Akili	0.00%	0.00%	0.00%	0.00%	0.00%
APYX Apyx Medical	0.00%	-4.92%	-4.61%	-38.17%	+47.21%
CNXU Conexeu Sciences	0.00%	-10.26%	-44.04%	-60.50%	+445,999,900.00%
RNXT RenovoRx	0.00%	-26.36%	+39.68%	+108.58%	+50.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKLI Akili	$0.43	$0.43	$0.19 ▼ $1.25	$34.01M	1.72	2.20 million shs	N/A
APYX Apyx Medical	$2.90 +0.3%	$3.61	$1.70 ▼ $5.08	$122.16M	1.31	129,347 shs	161,328 shs
CNXU Conexeu Sciences	$4.46 +4.9%	$8.09	$4.19 ▼ $18.79	$119.34M	N/A	272,290 shs	114,128 shs
RNXT RenovoRx	$1.76 -0.6%	$1.29	$0.70 ▼ $2.59	$79.43M	1.12	1.46 million shs	1.16 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKLI Akili	0.00%	0.00%	0.00%	0.00%	0.00%
APYX Apyx Medical	0.00%	-4.92%	-4.61%	-38.17%	+47.21%
CNXU Conexeu Sciences	0.00%	-10.26%	-44.04%	-60.50%	+445,999,900.00%
RNXT RenovoRx	0.00%	-26.36%	+39.68%	+108.58%	+50.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKLI Akili	0.00	N/A	N/A	N/A
APYX Apyx Medical	2.71	Moderate Buy	$6.60	127.59% Upside
CNXU Conexeu Sciences	2.00	Hold	$20.00	348.43% Upside
RNXT RenovoRx	2.75	Moderate Buy	$8.50	382.95% Upside

Current Analyst Ratings Breakdown

Latest AKLI, CNXU, APYX, and RNXT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	CNXU Conexeu Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (E-)
7/17/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	APYX Apyx Medical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/13/2026	APYX Apyx Medical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
6/29/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	CNXU Conexeu Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/24/2026	APYX Apyx Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/22/2026	CNXU Conexeu Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKLI Akili	$1.95M	17.46	N/A	N/A	$0.75 per share	0.58
APYX Apyx Medical	$52.84M	2.31	N/A	N/A	$0.39 per share	7.44
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	$1.12M	70.92	N/A	N/A	$0.15 per share	11.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKLI Akili	-$59.49M	-$0.61	N/A	N/A	N/A	-2,492.04%	-79.93%	-59.16%	N/A
APYX Apyx Medical	-$11.21M	-$0.20	N/A	N/A	N/A	-14.78%	-76.60%	-13.91%	11/5/2026 (Estimated)
CNXU Conexeu Sciences	-$3.92M	-$0.11	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	-$11.17M	-$0.31	N/A	N/A	N/A	-621.71%	-135.11%	-101.91%	11/12/2026 (Estimated)

Latest AKLI, CNXU, APYX, and RNXT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	RNXT RenovoRx	-$0.0725	-$0.05	+$0.0225	-$0.06	$0.70 million	$0.91 million
8/6/2026	Q2 2026	APYX Apyx Medical	-$0.0820	-$0.07	+$0.0120	-$0.07	$13.18 million	$13.88 million
6/15/2026	Q2 2026	CNXU Conexeu Sciences	N/A	-$0.11	N/A	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKLI Akili	N/A	N/A	N/A	N/A	N/A
APYX Apyx Medical	N/A	N/A	N/A	N/A	N/A
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKLI Akili	0.08	5.80	5.80
APYX Apyx Medical	3.19	5.68	4.53
CNXU Conexeu Sciences	N/A	14.93	14.93
RNXT RenovoRx	N/A	5.74	5.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKLI Akili	53.12%
APYX Apyx Medical	55.33%
CNXU Conexeu Sciences	N/A
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
AKLI Akili	10.10%
APYX Apyx Medical	15.90%
CNXU Conexeu Sciences	N/A
RNXT RenovoRx	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKLI Akili	130	78.73 million	70.78 million	No Data
APYX Apyx Medical	270	42.12 million	35.43 million	Optionable
CNXU Conexeu Sciences	4	26.76 million	N/A	N/A
RNXT RenovoRx	6	45.13 million	40.89 million	Not Optionable

AKLI, CNXU, APYX, and RNXT Headlines

Recent News About These Companies

RenovoRx FY2026 EPS Boosted by Ascendiant Capital Markets

September 4, 2026 | americanbankingnews.com

RenovoRx HC Wainwright presentation to highlight RenovoCath growth and Phase III TIGeR-PaC timeline

September 2, 2026 | msn.com

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

September 2, 2026 | globenewswire.com

FY2026 EPS Estimate for RenovoRx Increased by Analyst

September 2, 2026 | marketbeat.com

RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Up 137.8% in August

August 28, 2026 | marketbeat.com

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced ...

August 25, 2026 | finance.yahoo.com

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

August 25, 2026 | globenewswire.com

RenovoRx (NASDAQ:RNXT) Gains Attention After Compliance Update

August 21, 2026 | kalkinemedia.comK

RenovoRx regains Nasdaq compliance

August 21, 2026 | msn.com

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 21, 2026 | globenewswire.com

RenovoRx Regains Nasdaq Compliance on Minimum Bid Price

August 20, 2026 | tipranks.com

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

August 20, 2026 | globenewswire.com

HC Wainwright Has Positive Outlook of RenovoRx Q3 Earnings

August 18, 2026 | marketbeat.com

What is HC Wainwright's Forecast for RenovoRx Q3 Earnings?

August 17, 2026 | marketbeat.com

RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers

August 16, 2026 | marketbeat.com

RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen

August 15, 2026 | marketbeat.com

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Q2 FY2026 earnings call transcript

August 12, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2026 | zacks.com

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

August 12, 2026 | markets.businessinsider.com

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

August 11, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKLI, CNXU, APYX, and RNXT Company Descriptions

Akili NASDAQ:AKLI

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Apyx Medical NASDAQ:APYX

$2.90 +0.01 (+0.35%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.90 0.00 (-0.17%)

As of 09/11/2026 07:30 PM Eastern

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Conexeu Sciences NASDAQ:CNXU

$4.46 +0.21 (+4.94%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.46 0.00 (-0.11%)

As of 09/11/2026 07:41 PM Eastern

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

RenovoRx NASDAQ:RNXT

$1.76 -0.01 (-0.56%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.81 +0.05 (+2.84%)

As of 09/11/2026 07:42 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKLI, CNXU, APYX, and RNXT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKLI, CNXU, APYX, and RNXT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKLI, CNXU, APYX, and RNXT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKLI, CNXU, APYX, and RNXT Company Descriptions

Akili NASDAQ:AKLI

Apyx Medical NASDAQ:APYX

Conexeu Sciences NASDAQ:CNXU

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKLI, CNXU, APYX, and RNXT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKLI, CNXU, APYX, and RNXT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKLI, CNXU, APYX, and RNXT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKLI, CNXU, APYX, and RNXT Company Descriptions

Akili NASDAQ:AKLI

Apyx Medical NASDAQ:APYX

Conexeu Sciences NASDAQ:CNXU

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools